Reported 8 months ago
Gilead (GILD) has reported promising results from a study on its biannual shot for preventing HIV, showing 100% efficacy in women and adolescent girls in Africa. Analysts believe that Gilead's HIV portfolio, especially with treatments like pre-exposure prophylaxis, is a major contributor to the company's market capitalization. The success of this drug could potentially have a significant impact on Gilead's financial performance in the future.
Source: YAHOO